1 | 729588 | Effect of phospholipid depletion by phospholipases on the properties and formation of the multiple monoamine oxidase forms in the rat liver. | Eur J Biochem | 1978 Dec 1 |
1 |
2 | 883159 | [Inhibition of the activity of monoamine oxidases type A and B by derivatives of 2-propynylamine]. | Vopr Med Khim | 1977 Mar-Apr |
4 |
3 | 1094115 | Synthesis and biological activity of LH-RH analogs modified at the carboxyl terminus. | J Med Chem | 1975 Mar |
3 |
4 | 1433183 | Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. | J Med Chem | 1992 Oct 2 |
1 |
5 | 1567465 | The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. | Biochem Pharmacol | 1992 Apr 1 |
2 |
6 | 2128506 | Semicarbazide-sensitive amine oxidase activity in rat aortic cultured smooth muscle cells. | J Neural Transm Suppl | 1990 |
2 |
7 | 3707613 | Role of propiolaldehyde and other metabolites in the pargyline inhibition of rat liver aldehyde dehydrogenase. | Biochem Pharmacol | 1986 May 1 |
1 |
8 | 6615922 | [Kinetics of the inhibition of mitochondrial monoamine oxidases A and B from rat liver by 1-(indolyl-3)isopropylmethylpropargylamine]. | Biokhimiia | 1983 Jul |
1 |
9 | 7931256 | Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications. | J Neural Transm Suppl | 1994 |
1 |
10 | 8061623 | Relationship between the hydrophobic physicochemical parameters and biological activity of some monoamine oxidase inhibitory drugs. | Biochem Mol Biol Int | 1994 Apr |
1 |
11 | 8294932 | Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. | J Neurochem | 1994 Feb |
1 |
12 | 8469735 | [An increase in the radioprotective effect of O-methyltyramine and mezaton by monoamine oxidase inhibitors]. | Radiobiologiia | 1993 Jan-Feb |
2 |
13 | 10893719 | Synthesis and antiviral activity of C-5 substituted analogues of d4T bearing methylamino- or methyldiamino-linker arms. | Nucleosides Nucleotides Nucleic Acids | 2000 May-Jun |
1 |
14 | 10907720 | Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. | J Neural Transm (Vienna) | 1999 |
1 |
15 | 10996018 | Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. | Mech Ageing Dev | 2000 Jul 31 |
1 |
16 | 11205136 | Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl. | J Neural Transm Suppl | 2000 |
1 |
17 | 11377449 | Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma? | Surv Ophthalmol | 2001 May |
1 |
18 | 11454735 | Inhibition of rat liver microsomal CYP1A2 and CYP2B1 activity by N-(2-heptyl)-N-methyl-propargylamine and by N-(2-heptyl)-propargylamine. | Drug Metab Dispos | 2001 Aug |
1 |
19 | 11462787 | Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. | Ann N Y Acad Sci | 2001 Jun |
1 |
20 | 11489679 | Future of neuroprotection in Parkinson's disease. | Parkinsonism Relat Disord | 2001 Oct |
1 |
21 | 11795516 | Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy. | Ann N Y Acad Sci | 2001 Apr |
2 |
22 | 11860347 | The influence of metabolism on the MAO-B inhibitory potency of selegiline. | Curr Med Chem | 2002 Jan |
2 |
23 | 11961082 | Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. | J Pharmacol Exp Ther | 2002 May |
9 |
24 | 12043833 | Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. | Cell Mol Neurobiol | 2001 Dec |
3 |
25 | 12111453 | Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. | J Neural Transm (Vienna) | 2002 May |
1 |
26 | 12721812 | Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. | J Neural Transm (Vienna) | 2003 May |
3 |
27 | 14525944 | The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. | FASEB J | 2003 Dec |
1 |
28 | 14696044 | Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? | Bioessays | 2004 Jan |
2 |
29 | 15035819 | Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. | Inflammopharmacology | 2003 |
1 |
30 | 15382913 | CuBr-catalyzed efficient alkynylation of sp3 C-H bonds adjacent to a nitrogen atom. | J Am Chem Soc | 2004 Sep 29 |
1 |
31 | 15573406 | Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. | J Neurosci Res | 2005 Jan 1-15 |
4 |
32 | 15621213 | Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. | Mech Ageing Dev | 2005 Feb |
3 |
33 | 16027398 | Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. | J Clin Pharmacol | 2005 Aug |
2 |
34 | 16110345 | Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. | Drugs Today (Barc) | 2005 Jun |
2 |
35 | 16148027 | Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. | FASEB J | 2005 Nov |
13 |
36 | 16675649 | Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. | Am J Health Syst Pharm | 2006 May 15 |
2 |
37 | 16717254 | Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. | Neurology | 2006 May 23 |
2 |
38 | 16927880 | [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]. | Orv Hetil | 2006 Jul 9 |
1 |
39 | 17017568 | Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. | J Neural Transm Suppl | 2006 |
4 |
40 | 17511474 | Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. | Biochemistry | 2007 Jun 12 |
1 |
41 | 17529991 | Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. | Nat Struct Mol Biol | 2007 Jun |
1 |
42 | 17982885 | Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. | J Neural Transm Suppl | 2007 |
1 |
43 | 18035186 | Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. | Clin Ther | 2007 Sep |
1 |
44 | 18077571 | Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. | Ann N Y Acad Sci | 2007 Dec |
2 |
45 | 18488080 | Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. | Ther Clin Risk Manag | 2007 Jun |
1 |
46 | 18806608 | TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity. | J Cardiovasc Pharmacol | 2008 Sep |
2 |
47 | 19915070 | TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements. | J Pharmacol Exp Ther | 2010 Feb |
3 |
48 | 20148560 | Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. | J Am Chem Soc | 2010 Mar 10 |
2 |
49 | 20555137 | Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. | J Alzheimers Dis | 2010 |
4 |
50 | 21901055 | Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions. | Drug Target Insights | 2006 |
1 |